{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:56:25Z","timestamp":1778889385578,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7187","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1038\/nature06913","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T17:22:28Z","timestamp":1207156948000},"page":"548-552","source":"Crossref","is-referenced-by-count":827,"title":["The cancer biomarker problem"],"prefix":"10.1038","volume":"452","author":[{"given":"Charles L.","family":"Sawyers","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,4,2]]},"reference":[{"key":"BFnature06913_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMp0708162","volume":"358","author":"DJ Hunter","year":"2008","unstructured":"Hunter, D. J., Khoury, M. J. & Drazen, J. M. Letting the genome out of the bottle \u2014 will we get our wish? N. Engl. J. Med. 358, 105\u2013107 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnature06913_CR2","unstructured":"Committee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment. Cancer Biomarkers: the Promises and Challenges of Improving Detection and Treatment (eds Nass, S. J. & Moses, H. L.) (National Academies Press, Washington DC, 2007)."},{"key":"BFnature06913_CR3","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.1158\/1078-0432.CCR-07-2133","volume":"13","author":"MJ Ratain","year":"2007","unstructured":"Ratain, M. J. & Glassman, R. H. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin. Cancer Res. 13, 6545\u20136548 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnature06913_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/pst.269","volume":"6","author":"KJ Carroll","year":"2007","unstructured":"Carroll, K. J. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology. Pharm. Stat. 6, 253\u2013260 (2007).","journal-title":"Pharm. Stat."},{"key":"BFnature06913_CR5","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah, N. P. et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117, 2562\u20132569 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnature06913_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nature Rev. Cancer 7, 169\u2013181 (2007).","journal-title":"Nature Rev. Cancer"},{"key":"BFnature06913_CR7","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17, doi:10.1371\/journal.pmed.0020017 (2005).","journal-title":"PLoS Med."},{"key":"BFnature06913_CR8","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","volume":"25","author":"S Khambata-Ford","year":"2007","unstructured":"Khambata-Ford, S. et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230\u20133237 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnature06913_CR9","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa051918","volume":"353","author":"IK Mellinghoff","year":"2005","unstructured":"Mellinghoff, I. K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012\u20132024 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnature06913_CR10","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood.V108.11.2166.2166","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah, N. P. et al. Potent transient inhibition of BCR\u2013ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: implications for patient management and drug development. Blood 108, abstr. 2166 (2006).","journal-title":"Blood"},{"key":"BFnature06913_CR11","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73, doi:10.1371\/journal.pmed.0020073 (2005).","journal-title":"PLoS Med."},{"key":"BFnature06913_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jnci\/djk020","volume":"99","author":"M Dowsett","year":"2007","unstructured":"Dowsett, M. et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99, 167\u2013170 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnature06913_CR13","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","volume":"5","author":"TF Cloughesy","year":"2008","unstructured":"Cloughesy, T. F. et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5, e8, doi:10.1371\/journal.pmed.0050008 (2008).","journal-title":"PLoS Med."},{"key":"BFnature06913_CR14","doi-asserted-by":"publisher","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc. Natl Acad. Sci. USA 98, 10314\u201310319 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature06913_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781\u2013791 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnature06913_CR16","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-06-2701","volume":"13","author":"DR Shaffer","year":"2007","unstructured":"Shaffer, D. R. et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 2023\u20132029 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnature06913_CR17","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/nature06385","volume":"450","author":"S Nagrath","year":"2007","unstructured":"Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235\u20131239 (2007).","journal-title":"Nature"},{"key":"BFnature06913_CR18","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/nm1491","volume":"12","author":"A Potti","year":"2006","unstructured":"Potti, A. et al. Genomic signatures to guide the use of chemotherapeutics. Nature Med. 12, 1294\u20131300 (2006).","journal-title":"Nature Med."},{"key":"BFnature06913_CR19","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/nm1107-1276b","volume":"13","author":"KR Coombes","year":"2007","unstructured":"Coombes, K. R., Wang, J. & Baggerly, K. A. Microarrays: retracing steps. Nature Med. 13, 1276\u20131277 (2007).","journal-title":"Nature Med."},{"key":"BFnature06913_CR20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nm1437","volume":"12","author":"RK Thomas","year":"2006","unstructured":"Thomas, R. K. et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Med. 12, 852\u2013855 (2006).","journal-title":"Nature Med."},{"key":"BFnature06913_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/ng1975","volume":"39","author":"RK Thomas","year":"2007","unstructured":"Thomas, R. K. et al. High-throughput oncogene mutation profiling in human cancer. Nature Genet. 39, 347\u2013351 (2007).","journal-title":"Nature Genet."},{"key":"BFnature06913_CR22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","volume":"131","author":"K Rikova","year":"2007","unstructured":"Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190\u20131203 (2007).","journal-title":"Cell"},{"key":"BFnature06913_CR23","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1073\/pnas.0609139104","volume":"104","author":"R Mehrian-Shai","year":"2007","unstructured":"Mehrian-Shai, R. et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K\/Akt pathway activation in glioblastoma and prostate cancer. Proc. Natl Acad. Sci. USA 104, 5563\u20135568 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature06913_CR24","doi-asserted-by":"publisher","first-page":"7564","DOI":"10.1073\/pnas.0702507104","volume":"104","author":"LH Saal","year":"2007","unstructured":"Saal, L.H. et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. USA 104, 7564\u20137569 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature06913_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature04296","volume":"439","author":"AH Bild","year":"2006","unstructured":"Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353\u2013357 (2006).","journal-title":"Nature"},{"key":"BFnature06913_CR26","doi-asserted-by":"publisher","first-page":"16368","DOI":"10.1073\/pnas.0507904102","volume":"102","author":"F Diehl","year":"2005","unstructured":"Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl Acad. Sci. USA 102, 16368\u201316373 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature06913_CR27","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1056\/NEJMoa051931","volume":"353","author":"X Wang","year":"2005","unstructured":"Wang, X. et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353, 1224\u20131235 (2005).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature06913.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature06913","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature06913.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:15:31Z","timestamp":1684433731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature06913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":27,"journal-issue":{"issue":"7187","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["BFnature06913"],"URL":"https:\/\/doi.org\/10.1038\/nature06913","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}